GlassScriptPhysician profile
Ashish Chaddha
NPI 1376955492
$4,505.20
in general payments reported to CMS, 2019-2025
20 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $985 · 2021: $1,357 · 2022: $394 · 2023: $679 · 2024: $443 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,202.99 | 2020-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Medtronic, INC. | $1,137.49 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $688.09 | 2021-2025 | Bodyguardian, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $344.40 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.60 | 2022-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $138.11 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $115.12 | 2021-2024 | Xarelto |
| Heartflow, INC. | $107.72 | 2022-2025 | Ffrct |
| Abiomed | $93.64 | 2021 | |
| Pfizer INC. | $82.44 | 2023-2025 | |
| Cleerly, INC. | $74.17 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.54 | 2023-2025 | Lifevest |
| Baxter Healthcare | $58.74 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Amgen INC. | $50.85 | 2024-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $42.12 | 2023 | Inpefa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $35.02 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $27.08 | 2025 | Farxiga |
| W. L. Gore & Associates, INC. | $18.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $15.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Chaddha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.